- Conditions
- NASH With Fibrosis, MASH With Fibrosis
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more
Location Directory
Clinical trials in Chicago, Illinois
This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
17832
Shown on this page
12
Current sort
Recently updated
Location scope
Chicago, IL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 481–492 of 17,832 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Institutions in Chicago
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Cancer
- Interventions
- Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more
- Conditions
- Inguinal Hernia Bilateral, Inguinal Hernia Unilateral
- Interventions
- surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines, Watchful waiting with supportive care
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pneumococcal Disease
- Interventions
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 2,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 19 more
- Conditions
- Fibromyalgia
- Interventions
- AXS-14 (esreboxetine)
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Anaheim, California • Oceanside, California + 32 more
- Conditions
- Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
- Interventions
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 4
- States / cities
- Oakland, California • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
- Interventions
- Eye Tracker, Mouth Operated Joystick, Non-invasive electroencephalogram (EEG) Headset, Implantable Brain-Computer-Interface, Personal Assistive Technology, Voice Control
- Device
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypertension
- Interventions
- Core intervention (Fitbit tracking and BP health education), Aerobic training (AT), Dynamic resistance training (DRT), Isometric resistance training (IRT)
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Obesity, Smoking Cessation, Physical Inactivity
- Interventions
- multiple behavior change therapy
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure
- Interventions
- Hearo App
- Device
- Lead sponsor
- Cordio Medical
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Fairhope, Alabama • La Jolla, California • Loma Linda, California + 29 more
- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 309
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 230 more